SIGNIFICANT SYN FULL
SIGNIFICANT SYN TRIAL

– Fully subscribed rights issue, raised gross proceeds of 7.25 MEUR in May

– Directed issue, raised gross proceeds of 1.46 MEUR in April He has acted as the Chief Operating Officer of Herantis Pharma since 2018. Antti Vuolanto appointed as the CEO in July.In December, Nasdaq Stockholm AB approved Herantis’ delisting application regarding the secondary listing on the Nasdaq First North Growth Market Sweden.Selected for European Innovation Council (EIC) grant in December, of €2.5 million through their prestigious EIC Accelerator, with the option to receive additional funding through an equity investment, pending negotiation.

SIGNIFICANT SYN TRIAL

Submission of clinical trial application (CTA) for a Phase 1a study of HER-096 in December.After registering, you will receive a confirmation email containing information about joining the webinar.īusiness highlights January – December 2022 To register for this event, you need a Zoom account. Please join the webinar a few minutes in advance. Ī webinar (in English) will be held today, Maat 10:00 EET / 9:00 CET

SIGNIFICANT SYN FULL

The full report is attached to this release and is available in the company’s website. Herantis Pharma Plc (“Herantis ”), a company developing disease-modifying therapies for Parkinson’s disease, released today the company’s 2H & FY report for 2022. Qualifying for this highly competitive funding scheme is a great recognition of our HER-096 development,” commented CEO Antti Vuolanto. In December 2022, Herantis was selected to receive financing from European Innovation Council Accelerator program: a grant of €2.5 with the option to receive additional funding through an equity investment. We look forward to the first HER-096 human dose in 1H 2023 and to create additional value in 2023 through early clinical development and to pursue partnering opportunities for HER-096. The compelling preclinical data supports the potential of HER-096 to be a disease-modifying therapy for Parkinson’s disease with a unique mechanism of action.

“We made good progress in 2022 achieving encouraging preclinical results and submitting clinical trial application (CTA) for HER-096. Nothing else differs from the previous release.Ĭompany Release, March 7, 2023, at 19:40 EET/ 18:40 CET EET: the release category has been updated by removal of “insider information” and the Key Figures table is now included in the release. Correction to release sent on March 2 nd, 2023, at 8:00 a.m.

Significant syn